PLRX NASDAQ Week ended 31 Jul 2026

Weekly Investor Report

Pliant Therapeutics Inc · Healthcare · Biotechnology

Open interactive chart View report data
Latest close 1.04 USD
-4.6% latest week
Weekly setup

Weak trend

The weekly trend is not active. Price is -14.4% below the Trend Line and sits at 0.0% of its 52-week range. The latest completed week returned -4.6%, after a -11.1% four-week move. The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive. Options positioning is bearish with 42/100 conviction, while the latest news-sentiment score is 51/100. Near-term considerations: volume confirmation is below normal; earnings are due in 4d.

Setup score 19 out of 100
Latest Close 1.04 USD 31 Jul 2026
1W Return -4.6% latest completed week
4W Return -11.1% short-term follow-through
12W Return -14.8% quarterly tape
Trend Breadth 19.2% 10 of 52 weeks active
Volume Ratio 0.5x vs 13-week average
What is working
  • No strong opportunity cluster is confirmed yet; monitor trend and activity pressure.
What could go wrong
  • The trend backdrop is inactive, so price action has not confirmed a constructive regime.
  • Price is below the Trend Line, which keeps downside pressure in focus.
  • Price is below Fair Value, so the market is still discounting the latest tape.
  • Activity pressure is negative, which weakens the current setup.
What to watch next
  • Trend Line remains the key weekly regime level.
  • Activity pressure is the gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through -4.6% Latest completed week; four-week move -11.1%. Indicator stack 11/38 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Quiet Activity-pressure buy-signal status for institutional accumulation timing. Options pressure Bearish 42/100 conviction; expected move 33.0%. News sentiment 51/100 53 relevant articles in the latest sentiment read. Event risk 4d Next report is scheduled for 06 Aug 2026; event risk rises as the date approaches.
01 · Price action

Where price is—and whether the trend supports it

The weekly trend is not active. Price is -14.4% below the Trend Line and sits at 0.0% of its 52-week range. The latest completed week returned -4.6%, after a -11.1% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value
Price Trend Line Fair Value
02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 0.5x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction
6 Feb 13 Feb 20 Feb 27 Feb 6 Mar 13 Mar 20 Mar 27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul 31 Jul
Up week Down week
Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.0312-week average 0.04

12-week confirmation

Trend active0/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure5/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership0/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.03Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers

No recent accumulation markers. No reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is -11.1% over four weeks, -14.8% over 12 weeks, and -34.2% over one year. The current trend has remained active for 0 consecutive weeks.

Performance by holding period

1W-4.6%
4W-11.1%
12W-14.8%
26W-14.0%
52W-34.2%
Active trend streak0 weeks
Active weeks in one year10
Trend breadth19.2%

Activity pressure vs relative leadership

Activity pressureRelative leadership
Pressure-0.47Latest activity-pressure read.
Pressure change-45.7%Four-week change in activity pressure.
Leadership-29.72Latest relative-leadership reading.
RS change-11.8%Four-week change in relative leadership.
04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive.

Open full factor analysis
Factor week 26 Jul 2026 Financial statements through 31 Mar 2026 Field coverage 67% Model confidence 64%

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength44/100Blend of value, momentum, and quality. Underlying universe rank 57; rank 1 is best.
Value47/100Relative valuation strength. Underlying universe rank 54; rank 1 is best.
Quality45/100Profitability and accounting quality. Underlying universe rank 56; rank 1 is best.
Momentum47/100Medium-term price momentum. Underlying universe rank 54; rank 1 is best.
Growth47/100Revenue and earnings growth. Underlying universe rank 54; rank 1 is best.
How to read this

Quality and valuation are separate questions

A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E
-
Price divided by trailing earnings.
Price / sales
-
Market value relative to trailing revenue.
EV / EBITDA
-
Enterprise value relative to operating cash earnings.
Free-cash-flow yield
-133.1%
Free cash flow as a share of enterprise value.

Business quality

Margins and the return generated on invested capital.

Gross margin
-
Gross profit retained from each unit of revenue.
Operating margin
-
Operating profit retained from revenue.
Free-cash-flow margin
-
Free cash flow generated from revenue.
Return on invested capital
-47.8%
Operating return generated on invested capital.

Growth and financial strength

Recent business growth and accounting strength.

Revenue growth
-
Latest one-year revenue growth.
EPS growth
-
Latest one-year earnings-per-share growth.
Free-cash-flow growth
-
Latest one-year free-cash-flow growth.
Piotroski F-score
2/9
Nine-point accounting-strength checklist.

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

Dividend yield
-
Cash dividends relative to market value.
Buyback yield
-0.8%
Net share repurchases relative to market value.
Shareholder yield
-0.8%
Dividend yield plus net buyback yield.
Net debt / EBITDA
-0.1x
Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Options positioningBearish

PLRX shows bearish options pressure with a 42/100 conviction score, put-call volume ratio of 1.20, expected move of 33.0%, and Sharemaestro trend signal inactive.

Conviction42/100
Expected move33.0%
Put/call volume1.20
Pressure-21
Speculation3
Volatility96
Trend agreement86
Open options detail
Insider activity15 / 5

15 acquisitions and 5 disposals in the latest 180-day insider tape.

Acquisitions / disposals over the latest 180 days. Insider activity is context, not a stand-alone signal.
News sentiment51/100

Weighted news tone is neutral across 53 relevant articles.

8 positive · 39 neutral · 6 negative
Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal
06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings4dNext report is scheduled for 06 Aug 2026; event risk rises as the date approaches.
Options expected move33.0%Nearest-chain priced movement where available.
52-week drawdown-46.7%Distance below the 52-week high.
13-week volatility4.3%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

Weeks higher12 of 2614 weeks finished lower.
Best week+15.4%Week of 3 Apr.
Worst week-9.3%Week of 27 Mar.
Latest week-4.6%Week of 31 Jul.

Shape of recent returns

Strong gains5
Modest gains7
Flat weeks0
Modest losses4
Sharp losses10
Recent vol4.3%13-week weekly-return volatility.
Base vol7.4%52-week weekly-return volatility.
Up/down split24/26Count of positive and negative weeks in the 52-week window.
Average skew5.8% / -6.4%Average positive week versus average negative week.
07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape20/100

Trend, activity pressure, participation, and risk combine to a 20/100 tape read.

 Indicator analysis18/100

Latest 12-week confirmation: trend 0/12, activity pressure 5/12, relative leadership 0/12.

Activity pressure 0.03; No reversal markers Factors45/100

O'Shaughnessy factor stack blends value, quality, momentum, and confidence.

Buyback Yield rank 77; Small Cap Core rank 56 Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal Options54/100

PLRX shows bearish options pressure with a 42/100 conviction score, put-call volume ratio of 1.20, expected move of 33.0%, and Sharemaestro trend signal inactive.

Bearish · Put-side pressure · Expected move 33.0% Sentiment51/100

Weighted news tone is neutral across 53 relevant articles.

Pliant Therapeutics Inc (PLRX) Valuation: PE, PB & Fair Value Analysis Insiders15 / 5

15 acquisitions and 5 disposals in the latest 180-day insider tape.

 Earnings4d

Next report is scheduled for 06 Aug 2026; event risk rises as the date approaches.
WeekCloseReturnTrend LineFair ValuePressureLeadershipVolumeTrend
31 Jul 20261.04 USD-4.6%1.21 USD7.88 USD-0.47-29.721.3MOff
24 Jul 20261.09 USD-5.2%1.22 USD8.00 USD-0.22-26.823.7MOff
17 Jul 20261.15 USD2.7%1.23 USD8.11 USD-0.15-24.825.1MOff
10 Jul 20261.12 USD-4.3%1.23 USD8.21 USD-0.28-30.373.5MOff
3 Jul 20261.17 USD2.6%1.23 USD8.32 USD-0.33-26.591.6MOff
26 Jun 20261.14 USD-1.7%1.23 USD8.43 USD-0.28-28.251.9MOff
19 Jun 20261.16 USD2.7%1.25 USD8.54 USD-0.07-30.671.7MOff
12 Jun 20261.13 USD-1.7%1.26 USD8.67 USD0.27-31.171.5MOff
5 Jun 20261.15 USD-8.7%1.28 USD8.80 USD0.50-28.974.1MOff
29 May 20261.26 USD4.1%1.30 USD8.94 USD0.66-26.581.4MOff
22 May 20261.21 USD5.2%1.31 USD9.07 USD0.69-27.993.7MOff
15 May 20261.15 USD-5.7%1.33 USD9.20 USD0.74-31.211.3MOff
8 May 20261.22 USD1.7%1.34 USD9.34 USD0.88-27.872.0MOff
1 May 20261.20 USD-3.2%1.35 USD9.47 USD0.91-25.861.7MOff
How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.